Study to Evaluate Utilizing MRI for Earlier Diagnosis of Rheumatoid Arthritis


  • Study type

  • Study IDs

  • Describes the nature of a clinical study. Types include:

    • Observational study — observes people and measures outcomes without affecting results.
    • Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
    • Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
  • Site IRB
    • Rochester, Minnesota: 18-005455
    NCT ID: NCT03841279
    Sponsor Protocol Number: 18-005455

About this study

The primary purpose of this study is to describe the utilization and findings on magnetic resonance imaging (MRI) of the hands and feet in patients with seronegative rheumatoid arthritis (RA) (based on the ACR 1987 or 2010 classification criteria) compared to the findings seen in patients with seropositive disease (RF or ACPA positive).

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. If you need assistance understanding the eligibility criteria, please contact the study team.

See eligibility criteria

Inclusion Criteria:

  • Age ≥18 years.
  • Undifferentiated inflammatory arthritis suspected to be early RA by the evaluating clinician with clinical synovitis of ≥1 joint and ≥1 other tender joint but not fulfilling classification criteria.
  • Symptom duration ≤ 1 year.

Exclusion Criteria:

  • Unwillingness or inability to return to Mayo Clinic for research follow-up visits.
  • Current or previous (within the previous 6 months) use ofDMARDs – prednisone (≥10 mg/day), methotrexate,hydroxychloroquine, sulfasalazine, leflunomide, adalimumab, certolizumab, etanercept, golimumab, infliximab, abatacept, tocilizumab, sarilumab, tofacitinib, rituximab, or anakinra.
  • Contraindications to contrast-enhanced MRI ( renal insufficiency with estimated GFR ≤ 60 ml/min/1.73 m², extreme claustrophobia, metal implants or devices that contraindicate MRI).
  • Contraindications to contrast-enhanced PCD-CT (eGFR <30, history of previous contrast allergic reaction, history of premedication prior to iodinated contrast).
  • Personal history of another definite autoimmune or inflammatory rheumatic disease (e.g. rheumatoid arthritis, systemic lupus erythematosus, polymyositis, dermatomyositis, vasculitis, gout, or CPPD) diagnosed by a rheumatologist, excluding secondary Sjogren’s syndrome.
  • Women who are pregnant or nursing.
  • Personal history of psoriasis diagnosed by a primary care physician or dermatologist.
  • Personal history of inflammatory bowel disease diagnosed by a gastroenterologist.
  • Unsuitability to participate in the judgment of a study investigator.

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Kerry Wright, M.B.B.S.

Open for enrollment

Contact information:

Kathleen McCarthy-Fruin


More information


Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available


Mayo Clinic Footer